In Our Blood: A Profile of Stuart Orkin

By unraveling the molecular underpinnings of inherited blood disorders, the Boston Children’s Hospital researcher has provided the basis for therapies now being tested for beta-thalassemia and sickle cell disease.

Written byAnna Azvolinsky
| 9 min read
fetus dna disease blood cells

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

ABOVE: THE SCIENTIST STAFF

In the late 1970s, Stuart Orkin’s research landed him on the front page of The New York Times—and in a bit of hot water with a few colleagues. Orkin, then a newly minted assistant professor of pediatrics at Harvard Medical School and Boston Children’s Hospital, was developing a way to prenatally diagnose genetic disorders using DNA from the fetus. He was working with Boston Children’s hematologist David Nathan, as well as with collaborators at Yale who had developed a clinical technique to draw blood directly from a fetus during the second trimester using a fine needle. The technique “was quite a tour de force at the time,” Orkin recalls, but it was also risky, increasing the chance of miscarriage.

Despite the risk, the researchers wanted to use the technique to help a family from Turkey that had been referred to Nathan. The family carried a deletion ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • head shot of blond woman wearing glasses

    Anna Azvolinsky received a PhD in molecular biology in November 2008 from Princeton University. Her graduate research focused on a genome-wide analyses of genomic integrity and DNA replication. She did a one-year post-doctoral fellowship at Memorial Sloan Kettering Cancer Center in New York City and then left academia to pursue science writing. She has been a freelance science writer since 2012, based in New York City.

    View Full Profile

Published In

On Target July Issue The Scientist
July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Skip the Wait for Protein Stability Data with Aunty

Skip the Wait for Protein Stability Data with Aunty

Unchained Labs

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform